within Pharmacolibrary.Drugs.ATC.B;

model B01AC24
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.36,
    Cl             = 10.3 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 90 / 1000000,
    adminCount     = 1,
    Vd             = 0.088,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005833333333333333,
    Tlag           = 2100
  );

  annotation(Documentation(
    info ="<html><body><p>Ticagrelor is a direct-acting, oral, reversible P2Y12 receptor antagonist used as an antiplatelet agent for the prevention of atherothrombotic events in patients with acute coronary syndrome or a history of myocardial infarction. Approved for clinical use in many countries including the US and EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after single and multiple oral doses.</p><h4>References</h4><ol><li><p>Gelbenegger, G, &amp; Jilma, B (2022). Clinical pharmacology of antiplatelet drugs. <i>Expert review of clinical pharmacology</i> 15(10) 1177–1197. DOI:<a href=&quot;https://doi.org/10.1080/17512433.2022.2121702&quot;>10.1080/17512433.2022.2121702</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36065676/&quot;>https://pubmed.ncbi.nlm.nih.gov/36065676</a></p></li><li><p>Wang, ZT, et al., &amp; Cai, WM (2020). Effect of tea polyphenols on the oral and intravenous pharmacokinetics of ticagrelor in rats and its in vitro metabolism. <i>Journal of food science</i> 85(4) 1285–1291. DOI:<a href=&quot;https://doi.org/10.1111/1750-3841.15096&quot;>10.1111/1750-3841.15096</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32157685/&quot;>https://pubmed.ncbi.nlm.nih.gov/32157685</a></p></li><li><p>Ma, T, et al., &amp; Li, J (2022). SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor. <i>Frontiers in pharmacology</i> 13 1027627–None. DOI:<a href=&quot;https://doi.org/10.3389/fphar.2022.1027627&quot;>10.3389/fphar.2022.1027627</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36339534/&quot;>https://pubmed.ncbi.nlm.nih.gov/36339534</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B01AC24;
